Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of BRAF/NRAS mutation status. Here...
Gespeichert in:
| Veröffentlicht in: | Cell death & disease 2020-10, Vol.11 (10), p.882-882, Article 882 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 882 |
|---|---|
| container_issue | 10 |
| container_start_page | 882 |
| container_title | Cell death & disease |
| container_volume | 11 |
| creator | Das, Ishani Chen, Huiqin Maddalo, Gianluca Tuominen, Rainer Rebecca, Vito W. Herlyn, Meenhard Hansson, Johan Davies, Michael A. Egyházi Brage, Suzanne |
| description | Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of
BRAF/NRAS
mutation status. Herein, we elucidate the underlying mechanisms of the combination treatment effect to find biomarkers and novel targets for development of therapy that may provide clinical benefit by proteomic analysis of CMM cell lines and xenografts using mass spectrometry based analysis and reverse phase protein array. Identified candidates were validated using immunoblotting or immunofluorescence. Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment. Both in vitro and in vivo analyses showed that the combination treatment downregulated pRPS6KB1 and pRPS6, downstream of mTOR signaling, and IRS-1 in the insulin signaling pathway, specifically ablating IRS-1 nuclear signal. Silencing of RPS6 and IRS-1 alone had a similar effect on cell death, which was further induced when IRS-1 and RPS6 were concomitantly silenced in the CMM cell lines. Silencing of IRS-1 and RPS6 resulted in reduced sensitivity towards combination treatment. Additionally, we found that IRS-1 and RPS6KB1 expression levels were increased in advanced stages of CMM clinical samples. We could demonstrate that induced resistance towards combination treatment was reversible by a drug holiday. CD171/L1CAM, mTOR and PI3K-p85 were induced in the combination resistant cells whereas AXL and EPHA2, previously identified mediators of resistance to MAPK inhibitor therapy in CMM were downregulated. We also found that CD171/L1CAM and mTOR were increased at progression in tumor biopsies from two matched cases of patients receiving targeted therapy with BRAFi. Overall, these findings provide insights into the molecular mechanisms behind the afatinib and crizotinib combination treatment effect and leverages a platform for discovering novel biomarkers and therapy regimes for CMM treatment. |
| doi_str_mv | 10.1038/s41419-020-03097-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_467205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2471471950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c600t-d070de4cc062f4cdda4a1e7cffdc69a5204c41af3f12cbc81adee7c2bf682f173</originalsourceid><addsrcrecordid>eNp9kstq3DAUhk1paEKSF-iiCLrpxq0ky7K9KYSkaQOBQEi7FbIseZTY0lSS206eoQ_dM-PJFRpj8LH-71wk_Vn2luCPBBf1p8gII02OKc5xgZsqp6-yPYoZyVldN68fxbvZYYzXGJ6iwLTkb7JdCGpaEL6X_T1zC9vaZF2PrIvTYB2SrkPj1cUlirZ3clhL7QpJI4Gy7UZWwd76-Vf5sbUONO-Q8THpEFEbvARolXzyf6xC2hitUoQOSE1JOu2niEYoDfVdQqMepPOjPMh2jByiPtx-97Pvp1-ujr_l5xdfz46PznPFMU55hyvcaaYU5tQw1XWSSaIrZUyneCNL2LliRJrCEKpaVRPZaZBpa3hNDamK_Syf68bfejm1YhnsKMNKeGnFdukGIi0YrygugW_-yy-D7x6S7hIJKzGvMCcv9jqxP46ED724SQtBa04pB_7zzAM86k5pl4IcnrZ8oji7EL3_Jaqy4vOwH7YFgv856ZjEaKPSwzAfu6CspE1dwICAvn-GXvspwJWvqYrA22woOlMq-BiDNvfDECzWXhSzFwV4UWy8KCgkvXu8jfuUO-cBUGzPBSTX6_DQ-4Wy_wDJnPBu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471471950</pqid></control><display><type>article</type><title>Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><creator>Das, Ishani ; Chen, Huiqin ; Maddalo, Gianluca ; Tuominen, Rainer ; Rebecca, Vito W. ; Herlyn, Meenhard ; Hansson, Johan ; Davies, Michael A. ; Egyházi Brage, Suzanne</creator><creatorcontrib>Das, Ishani ; Chen, Huiqin ; Maddalo, Gianluca ; Tuominen, Rainer ; Rebecca, Vito W. ; Herlyn, Meenhard ; Hansson, Johan ; Davies, Michael A. ; Egyházi Brage, Suzanne</creatorcontrib><description>Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of
BRAF/NRAS
mutation status. Herein, we elucidate the underlying mechanisms of the combination treatment effect to find biomarkers and novel targets for development of therapy that may provide clinical benefit by proteomic analysis of CMM cell lines and xenografts using mass spectrometry based analysis and reverse phase protein array. Identified candidates were validated using immunoblotting or immunofluorescence. Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment. Both in vitro and in vivo analyses showed that the combination treatment downregulated pRPS6KB1 and pRPS6, downstream of mTOR signaling, and IRS-1 in the insulin signaling pathway, specifically ablating IRS-1 nuclear signal. Silencing of RPS6 and IRS-1 alone had a similar effect on cell death, which was further induced when IRS-1 and RPS6 were concomitantly silenced in the CMM cell lines. Silencing of IRS-1 and RPS6 resulted in reduced sensitivity towards combination treatment. Additionally, we found that IRS-1 and RPS6KB1 expression levels were increased in advanced stages of CMM clinical samples. We could demonstrate that induced resistance towards combination treatment was reversible by a drug holiday. CD171/L1CAM, mTOR and PI3K-p85 were induced in the combination resistant cells whereas AXL and EPHA2, previously identified mediators of resistance to MAPK inhibitor therapy in CMM were downregulated. We also found that CD171/L1CAM and mTOR were increased at progression in tumor biopsies from two matched cases of patients receiving targeted therapy with BRAFi. Overall, these findings provide insights into the molecular mechanisms behind the afatinib and crizotinib combination treatment effect and leverages a platform for discovering novel biomarkers and therapy regimes for CMM treatment.</description><identifier>ISSN: 2041-4889</identifier><identifier>EISSN: 2041-4889</identifier><identifier>DOI: 10.1038/s41419-020-03097-2</identifier><identifier>PMID: 33082316</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>1-Phosphatidylinositol 3-kinase ; 13 ; 13/1 ; 13/105 ; 13/106 ; 13/2 ; 13/51 ; 13/89 ; 631/67/1059/2326 ; 631/67/1059/602 ; 631/67/1813/1634 ; 631/67/1857 ; 82 ; 82/58 ; 82/80 ; Afatinib - pharmacology ; Antibodies ; Antineoplastic Agents - pharmacology ; Axl protein ; Biochemistry ; Biomarkers ; Biomedical and Life Sciences ; Cancer och onkologi ; Cell Biology ; Cell Culture ; Cell death ; Crizotinib - pharmacology ; Cytotoxicity ; Drug Resistance, Neoplasm - drug effects ; EphA2 protein ; Farmakologi och toxikologi ; Humans ; Immunoblotting ; Immunofluorescence ; Immunology ; Insulin ; Insulin receptor substrate 1 ; Klinisk medicin ; Life Sciences ; MAP kinase ; Mass spectroscopy ; Medicin och hälsovetenskap ; Medicinska och farmaceutiska grundvetenskaper ; Melanoma ; Melanoma - drug therapy ; Melanoma, Cutaneous Malignant ; Molecular modelling ; Protein arrays ; Protein Kinase Inhibitors - pharmacology ; Proto-Oncogene Proteins B-raf - metabolism ; Signal transduction ; Signal Transduction - drug effects ; Skin cancer ; Skin Neoplasms - drug therapy ; Targeted cancer therapy ; TOR protein ; TOR Serine-Threonine Kinases - drug effects ; Xenografts</subject><ispartof>Cell death & disease, 2020-10, Vol.11 (10), p.882-882, Article 882</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c600t-d070de4cc062f4cdda4a1e7cffdc69a5204c41af3f12cbc81adee7c2bf682f173</citedby><cites>FETCH-LOGICAL-c600t-d070de4cc062f4cdda4a1e7cffdc69a5204c41af3f12cbc81adee7c2bf682f173</cites><orcidid>0000-0002-2019-8072 ; 0000-0002-0524-2346 ; 0000-0003-0839-0739 ; 0000-0003-2297-6488 ; 0000-0002-0977-0912</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576205/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576205/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33082316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-286226$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:145067061$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Das, Ishani</creatorcontrib><creatorcontrib>Chen, Huiqin</creatorcontrib><creatorcontrib>Maddalo, Gianluca</creatorcontrib><creatorcontrib>Tuominen, Rainer</creatorcontrib><creatorcontrib>Rebecca, Vito W.</creatorcontrib><creatorcontrib>Herlyn, Meenhard</creatorcontrib><creatorcontrib>Hansson, Johan</creatorcontrib><creatorcontrib>Davies, Michael A.</creatorcontrib><creatorcontrib>Egyházi Brage, Suzanne</creatorcontrib><title>Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma</title><title>Cell death & disease</title><addtitle>Cell Death Dis</addtitle><addtitle>Cell Death Dis</addtitle><description>Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of
BRAF/NRAS
mutation status. Herein, we elucidate the underlying mechanisms of the combination treatment effect to find biomarkers and novel targets for development of therapy that may provide clinical benefit by proteomic analysis of CMM cell lines and xenografts using mass spectrometry based analysis and reverse phase protein array. Identified candidates were validated using immunoblotting or immunofluorescence. Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment. Both in vitro and in vivo analyses showed that the combination treatment downregulated pRPS6KB1 and pRPS6, downstream of mTOR signaling, and IRS-1 in the insulin signaling pathway, specifically ablating IRS-1 nuclear signal. Silencing of RPS6 and IRS-1 alone had a similar effect on cell death, which was further induced when IRS-1 and RPS6 were concomitantly silenced in the CMM cell lines. Silencing of IRS-1 and RPS6 resulted in reduced sensitivity towards combination treatment. Additionally, we found that IRS-1 and RPS6KB1 expression levels were increased in advanced stages of CMM clinical samples. We could demonstrate that induced resistance towards combination treatment was reversible by a drug holiday. CD171/L1CAM, mTOR and PI3K-p85 were induced in the combination resistant cells whereas AXL and EPHA2, previously identified mediators of resistance to MAPK inhibitor therapy in CMM were downregulated. We also found that CD171/L1CAM and mTOR were increased at progression in tumor biopsies from two matched cases of patients receiving targeted therapy with BRAFi. Overall, these findings provide insights into the molecular mechanisms behind the afatinib and crizotinib combination treatment effect and leverages a platform for discovering novel biomarkers and therapy regimes for CMM treatment.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>13</subject><subject>13/1</subject><subject>13/105</subject><subject>13/106</subject><subject>13/2</subject><subject>13/51</subject><subject>13/89</subject><subject>631/67/1059/2326</subject><subject>631/67/1059/602</subject><subject>631/67/1813/1634</subject><subject>631/67/1857</subject><subject>82</subject><subject>82/58</subject><subject>82/80</subject><subject>Afatinib - pharmacology</subject><subject>Antibodies</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Axl protein</subject><subject>Biochemistry</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Cancer och onkologi</subject><subject>Cell Biology</subject><subject>Cell Culture</subject><subject>Cell death</subject><subject>Crizotinib - pharmacology</subject><subject>Cytotoxicity</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>EphA2 protein</subject><subject>Farmakologi och toxikologi</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunofluorescence</subject><subject>Immunology</subject><subject>Insulin</subject><subject>Insulin receptor substrate 1</subject><subject>Klinisk medicin</subject><subject>Life Sciences</subject><subject>MAP kinase</subject><subject>Mass spectroscopy</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicinska och farmaceutiska grundvetenskaper</subject><subject>Melanoma</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Molecular modelling</subject><subject>Protein arrays</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Targeted cancer therapy</subject><subject>TOR protein</subject><subject>TOR Serine-Threonine Kinases - drug effects</subject><subject>Xenografts</subject><issn>2041-4889</issn><issn>2041-4889</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp9kstq3DAUhk1paEKSF-iiCLrpxq0ky7K9KYSkaQOBQEi7FbIseZTY0lSS206eoQ_dM-PJFRpj8LH-71wk_Vn2luCPBBf1p8gII02OKc5xgZsqp6-yPYoZyVldN68fxbvZYYzXGJ6iwLTkb7JdCGpaEL6X_T1zC9vaZF2PrIvTYB2SrkPj1cUlirZ3clhL7QpJI4Gy7UZWwd76-Vf5sbUONO-Q8THpEFEbvARolXzyf6xC2hitUoQOSE1JOu2niEYoDfVdQqMepPOjPMh2jByiPtx-97Pvp1-ujr_l5xdfz46PznPFMU55hyvcaaYU5tQw1XWSSaIrZUyneCNL2LliRJrCEKpaVRPZaZBpa3hNDamK_Syf68bfejm1YhnsKMNKeGnFdukGIi0YrygugW_-yy-D7x6S7hIJKzGvMCcv9jqxP46ED724SQtBa04pB_7zzAM86k5pl4IcnrZ8oji7EL3_Jaqy4vOwH7YFgv856ZjEaKPSwzAfu6CspE1dwICAvn-GXvspwJWvqYrA22woOlMq-BiDNvfDECzWXhSzFwV4UWy8KCgkvXu8jfuUO-cBUGzPBSTX6_DQ-4Wy_wDJnPBu</recordid><startdate>20201020</startdate><enddate>20201020</enddate><creator>Das, Ishani</creator><creator>Chen, Huiqin</creator><creator>Maddalo, Gianluca</creator><creator>Tuominen, Rainer</creator><creator>Rebecca, Vito W.</creator><creator>Herlyn, Meenhard</creator><creator>Hansson, Johan</creator><creator>Davies, Michael A.</creator><creator>Egyházi Brage, Suzanne</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AFDQA</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D8V</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-2019-8072</orcidid><orcidid>https://orcid.org/0000-0002-0524-2346</orcidid><orcidid>https://orcid.org/0000-0003-0839-0739</orcidid><orcidid>https://orcid.org/0000-0003-2297-6488</orcidid><orcidid>https://orcid.org/0000-0002-0977-0912</orcidid></search><sort><creationdate>20201020</creationdate><title>Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma</title><author>Das, Ishani ; Chen, Huiqin ; Maddalo, Gianluca ; Tuominen, Rainer ; Rebecca, Vito W. ; Herlyn, Meenhard ; Hansson, Johan ; Davies, Michael A. ; Egyházi Brage, Suzanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c600t-d070de4cc062f4cdda4a1e7cffdc69a5204c41af3f12cbc81adee7c2bf682f173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>13</topic><topic>13/1</topic><topic>13/105</topic><topic>13/106</topic><topic>13/2</topic><topic>13/51</topic><topic>13/89</topic><topic>631/67/1059/2326</topic><topic>631/67/1059/602</topic><topic>631/67/1813/1634</topic><topic>631/67/1857</topic><topic>82</topic><topic>82/58</topic><topic>82/80</topic><topic>Afatinib - pharmacology</topic><topic>Antibodies</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Axl protein</topic><topic>Biochemistry</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Cancer och onkologi</topic><topic>Cell Biology</topic><topic>Cell Culture</topic><topic>Cell death</topic><topic>Crizotinib - pharmacology</topic><topic>Cytotoxicity</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>EphA2 protein</topic><topic>Farmakologi och toxikologi</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunofluorescence</topic><topic>Immunology</topic><topic>Insulin</topic><topic>Insulin receptor substrate 1</topic><topic>Klinisk medicin</topic><topic>Life Sciences</topic><topic>MAP kinase</topic><topic>Mass spectroscopy</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicinska och farmaceutiska grundvetenskaper</topic><topic>Melanoma</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Molecular modelling</topic><topic>Protein arrays</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Targeted cancer therapy</topic><topic>TOR protein</topic><topic>TOR Serine-Threonine Kinases - drug effects</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Das, Ishani</creatorcontrib><creatorcontrib>Chen, Huiqin</creatorcontrib><creatorcontrib>Maddalo, Gianluca</creatorcontrib><creatorcontrib>Tuominen, Rainer</creatorcontrib><creatorcontrib>Rebecca, Vito W.</creatorcontrib><creatorcontrib>Herlyn, Meenhard</creatorcontrib><creatorcontrib>Hansson, Johan</creatorcontrib><creatorcontrib>Davies, Michael A.</creatorcontrib><creatorcontrib>Egyházi Brage, Suzanne</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SWEPUB Kungliga Tekniska Högskolan full text</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Kungliga Tekniska Högskolan</collection><collection>SwePub Articles full text</collection><jtitle>Cell death & disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Das, Ishani</au><au>Chen, Huiqin</au><au>Maddalo, Gianluca</au><au>Tuominen, Rainer</au><au>Rebecca, Vito W.</au><au>Herlyn, Meenhard</au><au>Hansson, Johan</au><au>Davies, Michael A.</au><au>Egyházi Brage, Suzanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma</atitle><jtitle>Cell death & disease</jtitle><stitle>Cell Death Dis</stitle><addtitle>Cell Death Dis</addtitle><date>2020-10-20</date><risdate>2020</risdate><volume>11</volume><issue>10</issue><spage>882</spage><epage>882</epage><pages>882-882</pages><artnum>882</artnum><issn>2041-4889</issn><eissn>2041-4889</eissn><abstract>Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of
BRAF/NRAS
mutation status. Herein, we elucidate the underlying mechanisms of the combination treatment effect to find biomarkers and novel targets for development of therapy that may provide clinical benefit by proteomic analysis of CMM cell lines and xenografts using mass spectrometry based analysis and reverse phase protein array. Identified candidates were validated using immunoblotting or immunofluorescence. Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment. Both in vitro and in vivo analyses showed that the combination treatment downregulated pRPS6KB1 and pRPS6, downstream of mTOR signaling, and IRS-1 in the insulin signaling pathway, specifically ablating IRS-1 nuclear signal. Silencing of RPS6 and IRS-1 alone had a similar effect on cell death, which was further induced when IRS-1 and RPS6 were concomitantly silenced in the CMM cell lines. Silencing of IRS-1 and RPS6 resulted in reduced sensitivity towards combination treatment. Additionally, we found that IRS-1 and RPS6KB1 expression levels were increased in advanced stages of CMM clinical samples. We could demonstrate that induced resistance towards combination treatment was reversible by a drug holiday. CD171/L1CAM, mTOR and PI3K-p85 were induced in the combination resistant cells whereas AXL and EPHA2, previously identified mediators of resistance to MAPK inhibitor therapy in CMM were downregulated. We also found that CD171/L1CAM and mTOR were increased at progression in tumor biopsies from two matched cases of patients receiving targeted therapy with BRAFi. Overall, these findings provide insights into the molecular mechanisms behind the afatinib and crizotinib combination treatment effect and leverages a platform for discovering novel biomarkers and therapy regimes for CMM treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33082316</pmid><doi>10.1038/s41419-020-03097-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2019-8072</orcidid><orcidid>https://orcid.org/0000-0002-0524-2346</orcidid><orcidid>https://orcid.org/0000-0003-0839-0739</orcidid><orcidid>https://orcid.org/0000-0003-2297-6488</orcidid><orcidid>https://orcid.org/0000-0002-0977-0912</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2041-4889 |
| ispartof | Cell death & disease, 2020-10, Vol.11 (10), p.882-882, Article 882 |
| issn | 2041-4889 2041-4889 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_467205 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; Springer Nature OA Free Journals; Nature Free; PubMed Central |
| subjects | 1-Phosphatidylinositol 3-kinase 13 13/1 13/105 13/106 13/2 13/51 13/89 631/67/1059/2326 631/67/1059/602 631/67/1813/1634 631/67/1857 82 82/58 82/80 Afatinib - pharmacology Antibodies Antineoplastic Agents - pharmacology Axl protein Biochemistry Biomarkers Biomedical and Life Sciences Cancer och onkologi Cell Biology Cell Culture Cell death Crizotinib - pharmacology Cytotoxicity Drug Resistance, Neoplasm - drug effects EphA2 protein Farmakologi och toxikologi Humans Immunoblotting Immunofluorescence Immunology Insulin Insulin receptor substrate 1 Klinisk medicin Life Sciences MAP kinase Mass spectroscopy Medicin och hälsovetenskap Medicinska och farmaceutiska grundvetenskaper Melanoma Melanoma - drug therapy Melanoma, Cutaneous Malignant Molecular modelling Protein arrays Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - metabolism Signal transduction Signal Transduction - drug effects Skin cancer Skin Neoplasms - drug therapy Targeted cancer therapy TOR protein TOR Serine-Threonine Kinases - drug effects Xenografts |
| title | Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibiting%20insulin%20and%20mTOR%20signaling%20by%20afatinib%20and%20crizotinib%20combination%20fosters%20broad%20cytotoxic%20effects%20in%20cutaneous%20malignant%20melanoma&rft.jtitle=Cell%20death%20&%20disease&rft.au=Das,%20Ishani&rft.date=2020-10-20&rft.volume=11&rft.issue=10&rft.spage=882&rft.epage=882&rft.pages=882-882&rft.artnum=882&rft.issn=2041-4889&rft.eissn=2041-4889&rft_id=info:doi/10.1038/s41419-020-03097-2&rft_dat=%3Cproquest_swepu%3E2471471950%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471471950&rft_id=info:pmid/33082316&rfr_iscdi=true |